A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers.
A single dose of the immunomodulator CGP A (MTP-PE) given intranasally to human volunteers 24 h prior to challenge with influenza A2 virus failed to protect against infection or ameriolate any subsequent illness.
Higgins
P G
PG
MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
Barrow
G I
GI
Galbraith
A W
AW
Frost
H
H
Tyrrell
D A
DA
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D009980:Influenza A virus / Q000302:isolation & purification; D007251:Influenza, Human / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010714:Phosphatidylethanolamines / Q000627:therapeutic use*; D011897:Random Allocation
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D010714:Phosphatidylethanolamines; C037144:mifamurtide; C007510:1,2-dipalmitoyl-3-phosphatidylethanolamine; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C035104:muramylNAc-Ala-isoGln-Lys-tripeptide